BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31509235)

  • 1. Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.
    Major A; Smith DE; Ghosh D; Rabinovitch R; Kamdar M
    Cancer; 2020 Jan; 126(1):189-201. PubMed ID: 31509235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second primary malignancy in diffuse large B-cell lymphoma patients: A SEER database analysis.
    Jiang S; Zhen H; Jiang H
    Curr Probl Cancer; 2020 Feb; 44(1):100502. PubMed ID: 31537411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.
    Keegan THM; Bleyer A; Rosenberg AS; Li Q; Goldfarb M
    JAMA Oncol; 2017 Nov; 3(11):1554-1557. PubMed ID: 28426850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
    Br J Haematol; 2017 Jul; 178(1):72-80. PubMed ID: 28542862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England.
    Miret M; Anderson A; Hindocha P; Cirneanu L; Lymperopoulou C; Markov E; Kizito W; Vegni FE
    Leuk Res; 2023 Apr; 127():107042. PubMed ID: 36812661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and mortality of second primary malignancies after lymphoma: a population-based analysis.
    Liu Y; Chu Y; Liu J; Ge X; Ding M; Li P; Liu F; Zhou X; Wang X
    Ann Med; 2023; 55(2):2282652. PubMed ID: 38010751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy.
    Rock CB; Chipman JJ; Parsons MW; Weil CR; Hutten RJ; Tao R; Tward JD; Shah HR; Hu B; Stephens DM; Gaffney DK
    Adv Radiat Oncol; 2022; 7(6):101035. PubMed ID: 36420188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of latency time on survival for adolescents and young adults with a second primary malignancy.
    Goldfarb M; Rosenberg AS; Li Q; Keegan THM
    Cancer; 2018 Mar; 124(6):1260-1268. PubMed ID: 29205296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population-based assessment.
    Brown AL; Arroyo VM; Agrusa JE; Scheurer ME; Gramatges MM; Lupo PJ
    Cancer; 2019 Oct; 125(20):3623-3630. PubMed ID: 31251393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk and survival of second primary malignancies following diagnosis of gastric mucosa-associated lymphoid tissue lymphomas: A population-based study.
    Yang Y; Yang Y; Yan S
    Curr Probl Cancer; 2021 Dec; 45(6):100735. PubMed ID: 33867153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second Primary Malignancies in Patients with Colorectal Cancer: A Population-Based Analysis.
    Jia H; Li Q; Yuan J; Sun X; Wu Z
    Oncologist; 2020 Apr; 25(4):e644-e650. PubMed ID: 31943509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk outcomes of second primary malignancy of patients with post-operative colorectal cancer.
    Yang J; Wu F; An H; Gan H
    Int J Colorectal Dis; 2023 Mar; 38(1):88. PubMed ID: 36995483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative population-based analysis of sinonasal diffuse large B-cell and extranodal NK/T-cell lymphomas.
    Dubal PM; Dutta R; Vazquez A; Patel TD; Baredes S; Eloy JA
    Laryngoscope; 2015 May; 125(5):1077-83. PubMed ID: 25546466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database.
    Kim JS; Liu Y; Ha KH; Qiu H; Rothwell LA; Kim HC
    Cancer Res Treat; 2020 Oct; 52(4):1262-1272. PubMed ID: 32599988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unstaged Diffuse Large B-Cell Lymphoma in the United States: Predictors and Patient Outcomes.
    Bista A; Sharma S; Rijwani T; Shah BK
    Anticancer Res; 2017 Apr; 37(4):1935-1939. PubMed ID: 28373463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
    Gundrum JD; Mathiason MA; Moore DB; Go RS
    J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk and outcome of acute myeloid leukaemia among survivors of primary diffuse large B-cell lymphoma: a retrospective observational study based on SEER database.
    Du Y; Wang Y; Li Q; Chang X; Zhang H; Xiao M; Xing S
    BMJ Open; 2022 Sep; 12(9):e061699. PubMed ID: 36581968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of radiation therapy in primary tonsil large B cell lymphoma: a SEER-based analysis.
    Jia J; Chen W
    Radiat Oncol; 2021 Oct; 16(1):193. PubMed ID: 34600539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States.
    Adjei Boakye E; Buchanan P; Hinyard L; Osazuwa-Peters N; Simpson MC; Schootman M; Piccirillo JF
    Int J Cancer; 2019 Jul; 145(1):143-153. PubMed ID: 30613963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do survivors of borderline ovarian tumors have susceptibility to secondary primary malignancies? A SEER population-based study.
    Wang J; Du Y; Kang Y
    Int J Gynaecol Obstet; 2024 Jun; 165(3):1229-1236. PubMed ID: 38205842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.